Sutro Biopharma has received $26m in a Series D financing, which will be used for the expansion of its proprietary immuno-oncology product pipeline. The company is currently using its cell-free protein synthesis technology to develop new ...
Genoa Pharmaceuticals and McMaster University have partnered to characterize the in vivo advantages and potential clinical impact of Genoa's inhaled GP-101 (aerosol pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF). ...
Tags: Pharmaceuticals, clinical impact, exploring mechanisms